title: Paclitaxel-eluting stents reduce neointimal hyperplasia compared to bare metal stents in saphenous vein grafts: intravascular ultrasonography analysis of the SOS (Stenting of Saphenous Vein Grafts) trial.
abstract: OBJECTIVE
  To compare the intravascular ultrasonography (IVUS) findings between saphenous vein grafts (SVG) treated with paclitaxel-eluting stents (PES) vs. bare metal stents (BMS) in the Stenting Of Saphenous Vein Grafts (SOS) trial.
  
  
  RESULTS
  Of the 80 SOS trial patients, 38 had both baseline and follow-up IVUS examination and were included in this substudy: 17 patients received 28 BMS in 26 lesions and 21 patients received 30 PES in 28 lesions. Quantitative IVUS analysis was performed to determine the volume of in-stent neointimal hyperplasia (NIH) - defined as the difference between stent volume and lumen volume in the stented segments. Baseline characteristics were similar between patients who did and did not undergo baseline and follow-up IVUS. Patients receiving BMS and PES had similar stent and lumen volumes immediately after stenting. At 12-month follow-up, compared to BMS, PES-treated lesions had significantly less NIH volume (3.4 vs. 21.9 mm³, p<0.001) and neointima hyperplasia progression (1.6 vs. 17.1 mm³, p<0.001). No significant differences were seen in the 5 mm segment proximal and distal to the stent.
  
  
  CONCLUSIONS
  Compared to BMS, use of PES in SVG lesions is associated with significantly lower NIH formation, which may help explain the improved clinical outcomes with PES in these lesions.
authors.affiliation: Veteran Affairs North Texas Healthcare System, Dallas, TX, USA.
authors.forename: Omar M
authors.initials: OM
authors.lastname: Jeroudi
authors.forename: Abdul-Rahman R
authors.initials: AR
authors.lastname: Abdel-Karim
authors.forename: Tesfaldet T
authors.initials: TT
authors.lastname: Michael
authors.forename: Christopher
authors.initials: C
authors.lastname: Lichtenwalter
authors.forename: James A
authors.initials: JA
authors.lastname: de Lemos
authors.forename: Owen
authors.initials: O
authors.lastname: Obel
authors.forename: Tayo
authors.initials: T
authors.lastname: Addo
authors.forename: Michele
authors.initials: M
authors.lastname: Roesle
authors.forename: Donald
authors.initials: D
authors.lastname: Haagen
authors.forename: Bavana V
authors.initials: BV
authors.lastname: Rangan
authors.forename: Deepa
authors.initials: D
authors.lastname: Raghunathan
authors.forename: Monica
authors.initials: M
authors.lastname: DaSilva
authors.forename: Bilal
authors.initials: B
authors.lastname: Saeed
authors.forename: Joseph K
authors.initials: JK
authors.lastname: Bissett
authors.forename: Rajesh
authors.initials: R
authors.lastname: Sachdeva
authors.forename: Vassilios V
authors.initials: VV
authors.lastname: Voudris
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Karyofillis
authors.forename: Biswajit
authors.initials: B
authors.lastname: Kar
authors.forename: James
authors.initials: J
authors.lastname: Rossen
authors.forename: Panayotis
authors.initials: P
authors.lastname: Fasseas
authors.forename: Peter
authors.initials: P
authors.lastname: Berger
authors.forename: Subhash
authors.initials: S
authors.lastname: Banerjee
authors.forename: Emmanouil S
authors.initials: ES
authors.lastname: Brilakis
mesh_terms: D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D054855:Drug-Eluting Stents; D006801:Humans; D006965:Hyperplasia / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D058426:Neointima / Q000517:prevention & control*; D017239:Paclitaxel / Q000008:administration & dosage*; D012501:Saphenous Vein / Q000000981:diagnostic imaging / Q000473:pathology / Q000637:transplantation*; D018084:Ultrasonography, Interventional
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel